December 11th 2024
Discover 2024 skin cancer breakthroughs, including FDA approvals, innovative therapies, and updated clinical guidelines for melanoma and nonmelanoma care.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Innovative Insights in Skin Cancer Prognosis, Gene Expression Profiling, and Early Career Tips
October 26th 2024Aaron Farberg, MD, explores advancements in melanoma and cSCC prognostic tools, the role of gene expression profiling in inflammatory diseases, and initiatives aimed at supporting early-career dermatologists at Fall Clinical 2024.
Neoadjuvant Intralesional 5-Fluorouracil Injection: Improved SCC Treatment in Older Patients
October 14th 2024In October's cover feature, Nicole A. Negbenebor, MD, FAAD, discusses the benefits of intralesional 5-fluorouracil injection for older patients with squamous cell carcinoma who may elect to delay therapy or are not ideal candidates for surgery.
Innovative Melanoma Treatment Among NCInnovation's $5.2 Million Research Funding Recipients
July 18th 2024Michelle Bolas and Rukiyah T. Van Dross-Anderson, PhD, discuss the significance of NCInnovations’ funding and the clinical impact of Van Dross-Anderson's research in patients with advanced melanoma.